Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Myeloid Leukemia, Chronic
|
115 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.800 | 0.943 | 105 | 2001 | 2020 | ||||||
leukemia
|
144 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.100 | 1.000 | 18 | 2004 | 2018 | ||||||
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
|
11 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.100 | 0.882 | 17 | 2006 | 2019 | ||||||
Childhood Leukemia
|
140 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.100 | 1.000 | 13 | 2009 | 2018 | ||||||
Blast Phase
|
14 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.070 | 0.857 | 7 | 2006 | 2019 | ||||||
Neoplasms
|
1644 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.060 | 1.000 | 6 | 2009 | 2020 | ||||||
Acute lymphocytic leukemia
|
222 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.050 | 0.800 | 5 | 2007 | 2015 | ||||||
Acute lymphoblastic leukemia with lymphomatous features
|
12 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.700 | 1.000 | 3 | 2002 | 2014 | ||||||
Leukemia, Myeloid, Chronic-Phase
|
1 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.030 | 1.000 | 3 | 2010 | 2013 | ||||||
Adult Acute Lymphocytic Leukemia
|
154 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.020 | 1.000 | 2 | 2009 | 2010 | ||||||
Childhood Acute Lymphoblastic Leukemia
|
261 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.020 | 1.000 | 2 | 2009 | 2010 | ||||||
Precursor B-cell lymphoblastic leukemia
|
23 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.020 | 1.000 | 2 | 2009 | 2019 | ||||||
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
168 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.020 | 1.000 | 2 | 2007 | 2012 | ||||||
Central nervous system leukaemia
|
1 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
|
1 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||||
Chronic eosinophilic leukemia
|
9 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Gastrointestinal Stromal Tumors
|
154 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1 | 2019 | 2019 | |||||||
Graft-vs-Host Disease
|
25 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Idiopathic Hypereosinophilic Syndrome
|
5 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Leukemogenesis
|
25 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2007 | 2007 | ||||||
Philadelphia chromosome positive chronic myelogenous leukemia
|
3 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||||
Philadelphia positive acute lymphocytic leukaemia
|
1 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Refractory cancer
|
9 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2006 | 2006 | ||||||
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
|
1 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||||
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
4 | 0.672 | 0.160 | 9 | 130872896 | missense variant | C/T | snv | 0.700 | 0 |